FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Publishes Advisory Committee Public Comment Guidance

[ Price : $8.95]

FDA issues a guidance for people who want to comment during advisory committee sessions.

Teva Plans NDA for Multiple Sclerosis

[ Price : $8.95]

Teva Pharmaceutical Industries says it could file an NDA late next year after reporting positive Phase 3 trials involving oral laq...

Review Period Set for Ilaris

[ Price : $8.95]

Federal Register Notice: FDA determines the regulatory review period for Novartis Ilaris for the purpose of patent extension.

FDA Sets Bepreve Review Period

[ Price : $8.95]

Federal Register Notice: FDA determines the regulatory review period for Ube Industries Bepreve for the purpose of patent extensio...

Sabril Review Period Set

[ Price : $8.95]

Federal Register Notice: FDA determines the regulatory review period for Lundbeck, Inc.s Sabril for the purpose of patent extensio...

Now McNeil Recalls All Rolaids Lots

[ Price : $8.95]

Capping other quality failures this year, McNeil recalls all U.S. lots of three Rolaids products after consumers report finding wo...

Agency Aiming to Ease Burden Caused by REMS: Woodcock

[ Price : $8.95]

CDER director Janet Woodcock tells an industry meeting that the agency needs to make the risk evaluation and mitigation strategy (...

White House Panel Urges Faster, Wider Health Data Use

[ Price : $8.95]

The Presidents Council of Advisors on Science and Technology urges rapid decisions to establish a universal exchange language for ...

FDA Lifts Hold on PharmAthene Anthrax Anti-toxin

[ Price : $8.95]

FDA lifts a partial clinical hold on PharmAthene for its clinical testing of an anthrax anti-toxin, Valortim.

CDRH Completes 86% of Strategic Priority Actions

[ Price : $8.95]

CDRH says it completed 86% of the strategic priority tasks it wanted to accomplish in FY 2010.